‘Encouraging’ findings
Commenting for this news organization, Daniel Goldenholz, MD, PhD, assistant professor, Harvard Beth Israel Deaconess Medical Center, Boston, praised the study design.
“It allows for comparison between different treatments, as well as a placebo control group,” said Dr. Goldenholz, who added, “There appears to be good follow-up” as well.
The fact that medication may provide some cognitive benefit for patients with TLE is “very encouraging,” he said.
He noted many patients with TLE complain of memory or language problems. “So, this is a major concern.”
However, he cautioned about side effects. “Putting all temporal lobe epilepsy patients who say that they have memory problems or language problems on these medications could have some serious consequences.”
The study was funded by a Department of Health Research grant from the government of India. Dr. Goldenholz is on the advisory board for epilepsy AI, Eyzs, and Magic Leap.
A version of this article first appeared on Medscape.com.